Rinvoq Approved for Active Non-Radiographic Axial Spondyloarthritis

The FDA has approved Rinvoq (upadacitinib) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Related Keywords

Thomas Hudson ,Assessment In Spondyloarthritis International Society ,Drug Administration ,Spondyloarthritis International Society ,Patient Global Assessment ,Disease Activity ,Bath Ankylosing Spondylitis Functional Index ,Ankylosing Spondylitis Quality ,Accessed October ,